Novartis Acquires Myricx Bio (ADC NMTi Payload Platform) for Up to $1.5 Billion

Novartis to Acquire Excellergy for up to $2 Billion

March 27, 2026

Biotechnology

Novartis entered into an agreement to acquire Excellergy, a private biotechnology company developing next-generation anti-IgE therapies, in a deal valued at up to $2 billion including upfront and milestone payments. The acquisition will bring Excellergy’s lead asset, Exl-111 (a potentially first-in-class trifunctional effector cell response inhibitor), into Novartis’ allergy and immunology pipeline.

Novartis Acquires Anthos Therapeutics for Up to $3.1B

February 11, 2025

Pharmaceuticals

Blackstone Life Sciences and Anthos Therapeutics announced that Novartis will acquire Anthos for up to $3.1 billion, including a $925 million upfront payment to Anthos shareholders. The deal is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals. Novartis later completed the acquisition, valuing the transaction at up to $3.1 billion with the $925 million upfront payment.

Novartis Acquires Mariana Oncology

May 2, 2024

Biotechnology

Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.

Novartis Acquires DTx Pharma

July 17, 2023

Biotechnology

Novartis has acquired DTx Pharma, a San Diego–based preclinical biotechnology company, for an upfront payment of USD 500 million plus contingent milestone payments. The deal brings DTx's FALCON siRNA delivery platform and lead program DTx-1252 (orphan-designated for CMT1A) into Novartis to strengthen its neuroscience pipeline and xRNA capabilities.

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

Novaremed AG Acquires Metys Pharmaceuticals AG

September 7, 2021

Pharmaceuticals

Novaremed AG acquired Metys Pharmaceuticals AG in an all-share transaction, integrating Metys' clinical and preclinical non-opioid pain programs (including MP-101 and MP-103) into Novaremed's pipeline. The deal broadens Novaremed's focus from painful diabetic peripheral neuropathy (PDPN) to include chemotherapy-induced peripheral neuropathy (CIPN) and strengthens leadership with the election of Andrew J. Oakley to Novaremed's board.